Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.

Blood advances - 27 Mar 2018

Czogalla Katrin J, Liphardt Kerstin, Höning Klara, Hornung Veit, Biswas Arijit, Watzka Matthias, Oldenburg Johannes

Abstract excerpt

Vitamin K reduction is catalyzed by 2 enzymes in vitro: the vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) and its isozyme VKORC1-like1 (VKORC1L1). In vivo, VKORC1 reduces vitamin K to sustain γ-carboxylation of vitamin K-dependent proteins, including coagulation factors. Inhibition of VKORC1 by oral anticoagulants (OACs) is clinically used in therapy and in prevention of thrombosis. However, OACs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Molecular Conformation

Share to Molecular Docking Simulation

Share to Quantitative Structure-Activity Relationship

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 29581108
DOI: 10.1182/bloodadvances.2017006775
PMCID: PMC5873226

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites.PMID 29581108Read ↗

Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.Semantic proximity Read ↗

Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.Semantic proximity Read ↗

VKORC1 and the vitamin K cycle.Semantic proximity Read ↗

The vitamin K oxidoreductase VKORC1L1 prevents oxidative stress in hepatocytes and protects from MASLD and hepatocellular carcinomaSemantic proximity Read ↗

Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfacesSemantic proximity Read ↗

The VKORC1 ER-luminal loop mutation (Leu76Pro) leads to a significant resistance to warfarin in black rats (Rattus rattus).Semantic proximity Read ↗

Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.Semantic proximity Read ↗

Structural Modeling Insights into Human VKORC1 Phenotypes.Semantic proximity Read ↗

A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.Semantic proximity Read ↗

Comparative genetics of warfarin resistance.Semantic proximity Read ↗

Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.Semantic proximity Read ↗

Avian interspecific differences in VKOR activity and inhibition: Insights from amino acid sequence and mRNA expression ratio of VKORC1 and VKORC1L1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.